Molecular Targets for Endometriosis Therapy: Where We Are and Where We Are Going?

Fabio Barra, Antonio Simone Laganà, Jvan Casarin, Fabio Ghezzi, Lorenzo Ferro Desideri, Carolina Scala, Simone Ferrero
International journal of fertility & sterility · 2019 · vol. 13(2) , pp. 89–92 · doi:10.22074/ijfs.2019.5736 · PMID:31037916 · PMC6500084 · W3021327785
editorial OA: gold CC0 ⤵ 9 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Numerous investigational drugs targeting specific biological mechanisms for endometriosis have been proposed, with some hormonal treatments nearing clinical use, while others require extensive research to assess efficacy and tolerability.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

This review discusses molecular targets proposed for endometriosis therapy and surveys where therapeutic target research stands and what directions are emerging, drawing on published mechanistic and preclinical evidence for various pathways implicated in disease. It synthesizes current understanding of multiple classes of targets rather than reporting original experiments, and it acknowledges the complexity and heterogeneity of the condition as a key challenge for translating molecular findings into effective treatments. The major caveat is that the evidence base spans different experimental models and stages of development, which limits straightforward conclusions about clinical efficacy. This paper is centrally about endometriosis — it focuses on molecular targets for endometriosis therapy and summarizes current progress and future directions.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

In conclusion, a high number of new investigational drugs targeting specific biological mechanisms have recently been proposed for treatment of endometriosis. Although the use of new hormonal treatments, such as GnRH-antagonists, is being deeply tested in the last clinical studies appearing relatively near to introduce into clinical practice, the majority of other innovative agents and targets have been tested only in vitro and in the animal model. Thus, more extensive research is mandatory to assess their efficacy and tolerability. In particular, only a minority of these drugs seems suitable for future investigations, considering the cornerstones of the endometriosis management, as well as possible side-effects and impact on quality of life.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (30)

Cited by (9)

Source provenance

europepmc
last seen: 2026-06-12T06:13:51.797165+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:22:48.502547+00:00
License: CC0 · commercial use OK